Picroliv

PreclinicalSmall molecule

Picroliv is one of 26 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Non-Alcoholic Fatty Liver DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Non-Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

6 2

Avandia

Jazz Pharmaceuticals

Approved

1 3

Actigall

Calciferol

Uloric

Crestor

Bayer Aspirin

Januvia

ZZydus Therapeutics Inc.

Approved

3 9

Jardiance

Boehringer Ingelheim

Approved

2 10

Glucophage

EMD Serono

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Fatty Liver Disease1 trial

Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease

Enrolling by invitation·BBioagile Therapeutics Pvt. Ltd.·N/A·NCT07452744·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Picroliv. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Picroliv compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Picroliv. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioagile Therapeutics Pvt. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBioagile Therapeutics Pvt. Ltd.

Picroliv

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News